Is central nervous system prophylaxis necessary in ocular XXXX ?

@entity1 @entity706 @entity5 @entity3002 @entity1072 @entity1892
PURPOSE: To examine the frequency of @entity3002 (CNS) from @entity706 and to evaluate whether CNS prophylaxis is appropriate for these @entity5 . @entity1 AND METHODS: Seventy-one @entity1 with biopsy-confirmed @entity706 were evaluated between 1989 and 1995. The @entity706 were subclassified histopathologically according to the new Revised @entity706 (REAL) criteria. Molecular genetic analysis of @entity5 cell DNA was done by Southern blot. @entity1 had a complete ophthalmologic evaluation and metastatic work-up and were then routinely followed up by an ophthalmologist and a medical oncologist. RESULTS: The 34 @entity1 and 37 @entity1 studied had a median age of 67 years (23 to 92). Ocular @entity706 were situated in the orbit in 54 @entity1 , in the conjunctiva in 14 @entity1 , and in the eyelid in 3 @entity1 . Bilateral involvement occurred in 11 @entity1 . The most common histologic diagnoses were (54 @entity1 , 76%) extra-nodal marginal @entity706 and @entity1072 in 10 @entity1 (14%). Molecular genetic analysis performed in all @entity1 confirmed a monoclonal B-cell population in 55 @entity1 (77%), including a single rearrangement of the immunoglobulin heavy chain gene in 14 @entity1 , and more than two rearrangements in 41 @entity1 . No @entity1 had isolated T-cell gene rearrangements. @entity706 was diagnosed in 43 @entity1 (61%), 17 @entity1 (24%) were found to have concurrent @entity706 on metastatic work-up and 11 @entity1 (15%) had a previous diagnosis of @entity706 before the onset of their @entity5 . The median duration of follow-up was 20 months. Overall, 32 @entity1 (45%) had @entity5 , which remained localized to the orbit adnexa. Eleven @entity1 (15%) relapsed, but none had eye or central nervous system involvement nor required CNS-directed therapy. Although eight @entity1 died, only two died as a direct result of @entity706 . No @entity1 received CNS prophylaxis with either intrathecal chemotherapy and/or radiation therapy. CONCLUSION: Ocular @entity706 are rare non-Hodgkin's @entity1892 . Metastatic involvement of the eye or central nervous system is rare and CNS prophylaxis with radiotherapy or chemotherapy is unnecessary.
